The ISEQ plummeted almost 120 points today to close at 5,308.16, with Elan shares losing 11% of their value.

Elan Corporation and Wyeth Pharmaceuticals last night announced key findings from a clinical trial of a new Alzheimers treatment, AN-1792, at the International Conference on Alzheimers Disease and Related Disorders in Philadelphia.